ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

CEPI

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa fever		University of Oxford	IAVI		
MERS	Uvax	IDT; Barinthus/ University of Oxford			
Nipah		PHV	University of Oxford		
Rift Valley fever	UC Davis; Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
Chikungunya				IVI/Bharat	Valneva
COVID-19*					SK Bioscience; Biological E; Moderna; Clover; Novavax; AZ/Oxford; University of Hong Kong
Broadly protective Betacoronavirus	VIDO; Panacea/ THSTI; IVI consortium; CPI/CalTech; Bharat/U Syd/ExcellGene; Intravacc; SK Bioscience				
Mpox		BioNTech			

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

CEPI

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Disease X	Akagera, POP BIO, Chungbuk University, Gennova*, University of Queensland, Emervax, Moderna, HMRI, SK bio, Imperial, University of Oxford, Nagasaki University, Boost Biopharma, VitriVax, ACM Bio, Abera Bioscience, IVI consortium, Sinergium	Centivax			
Broadly protective Filovirus vaccines	Adaptvac, Oxford/ Leipzig/ Moderna, Stanford				

(*) Gennova funding supports platform optmisation and development of candidate vaccines against Rabies and Nipah virus.

All .

DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
Lassa fever	University of Oxford	Phase I	Viral Vector	Up to $19 million‡
	IAVI	Phase II	Viral Vector	Up to $64.4 million
MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to $47 million‡
	IDT	Phase I	Viral vector	Up to $36 million
	Uvax bio	Preclinical	Protein based	Up to $2.6 million
Nipah	University of Oxford	Phase II	Viral Vector	Up to $19 million‡
	PHV	Phase I	Viral vector	Up to $43.6 million
Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to $40 million
	Wageningen University	Phase I	Live attenuated	Up to $38.4 million
	University of Oxford and KEMRI - Wellcome Trust	Phase II	Viral Vector	Up to $3.7 million
	Afrigen	Preclinical	mRNA	Up to $6.2 million
Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated virus	Up to $14.1 million
	Valneva	Registration	Live attenuated	Up to $65.9 million
COVID-19	SK Bioscience	Registration	Protein based	Up to $210 million
	Biological E	Registration	Protein based	Up to $14 million
	Moderna	Registration	Protein based	Up to $1 million
	Clover	Registration	Protein based	Up to $397.4 million
	University of Hong Kong	Registration	Live attenuated	Up to $5.4 million
	AZ/University of Oxford	Registration	Viral vector	Up to $384 million
	Novavax	Registration	Protein based	Up to $399 million
Mpox	BioNTech	Phase I/II	mRNA	Up to $72 million**

(‡) Includes Lassa, MERS and Nipah funding

** Funding is part of a total investment of up to $90m.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

Broadly protective Betacoronavirus	IVI Consortium	Preclinical	mRNA	Up to $23.9 million
	VIDO	Preclinical	Protein based	Up to $22 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to $19.9 million
	CPI/Caltech	Preclinical	Protein based	Up to $30 million
	SK Bioscience	Preclinical	Protein based	Up to $50 million
	Panacea/THSTI	Preclinical	Protein based	Up to $12.5 million
	Intravacc	Preclinical	Protein based	Up to $4.8 million
Disease X	Abera Bioscience	Preclinical	Protein based	Up to $1.5 million
	Akagera	Preclinical	mRNA	Up to $1.5 million
	ACM Bio	Preclinical	mRNA	Up to $2.9 million
	Boost Biopharma	Preclinical	Protein based	Up to $5 million
	Centivax	Phase I	mRNA	Up to $5.0 million
	Chungbuk National University	Preclinical	SaRNA	Up to $0.9 million
	Emervax	Preclinical	CircRNA	Up to $2.2 million
	Gennova	Preclinical	mRNA	Up to $16.98 million‡‡
	HMRI	Preclinical	CircRNA	Up to $3.8 million
	Imperial College London	Preclinical	SaRNA	Up to $8.4 million
	IVI, KDCA, ST Pharm, Seoul National University	Preclinical	mRNA	Up to $16 million
	Moderna	Phase II	mRNA	Up to $54.3 million
	Nagasaki University	Preclinical	mRNA	Up to $5 million
	University of Oxford	Preclinical	Viral Vector	Up to $80 million
	POP BIO	Preclinical	Protein based	Up to $1.5 million
	University of Queensland	Preclinical	Protein based	Up to $10.6 million
	Sinergium	Preclinical	mRNA	Up to $1 million
	SK Bioscience	Preclinical	mRNA	Up to $40 million
	VitriVax	Preclinical	Inactivated virus/Protein based	Up to $5 million
Broadly protective Filovirus vaccines	AdaptVac	Preclinical	Virus-like particle	Up to $12.4 million
	Stanford School of Medicine	Preclinical	Protein nanoparticle	Up to $18 million
	University of Oxford, Leipzig Institute for Drug Discovery, Moderna	Preclinical	Viral vector and mRNA	Up to $26.7 million

(‡‡) Includes $13.38 million for funding a Nipah candidate and $3.6 for funding for a Rabies candidate/platform optimisation.